Recurrent Erysipelas: 47 Cases

Abstract

Background:Recurrence is a common complication of erysipelas (cellulitis). Objectives:Todescribe the characteristics of patients with recurrent erysipelas and thereby, identify potential risk factors and evaluate prophylaxis efficacy. Methods:Data were retrospectively recorded from the files of 47 patients admitted to hospital between 1995 and 2003 for erysipelas recurrence. Studied variables included: general condition, regional and local factors, e.g. broken cutaneous barrier. Patient characteristics were used to construct tree-based models according to the classification and regression tree methodology. Results: Our patients suffered a mean of 4.1 recurrences. Cutaneous barrier disruption was observed in 81%, mainly intertrigo (60%). Antibiotic prophylaxis was taken by 68% of the patients for 30.6 months. After 1 and 2 years, 84 and 72% of the patients, respectively, were recurrence-free. Conclusion: Our results showed that erysipelas recurrence has the same risk factors as single episodes and underlines the potential benefit of oral or parenteral antibiotic prophylaxis to prevent recurrences.

Epidemiology and Comorbidity of Erysipelas in Primary Care

“…The risk factors in the patient group with recurrent erysipelas differ little from the group with only one episode as also described by Leclerc et al [21]. Like Pavlotsky et al [11], we found a higher frequency of obesity and dermatophytosis in the group of patients with more episodes.…”

Complicated course of facial cellulitis caused by Staphylococcus aureus in a 13-year-old boy with neutropenia — an adverse event analysis

“…The purpose of hospitalisation should also be the detection of complications. The most severe complications of SSTI are sepsis, meningitis, toxic shock syndrome, encephalitis, cavernous sinus thrombosis, necrotizing fasciitis and septic arthritis; the most common are recurrent infections, hemorrhagic, bullous, cutaneous abscesses and local necrotising lesions [4,5,9,11,24]. The detection of complications influences further management.…”

“…Specifically, in bullous erysipelas, S. aureus was reported in 50% of cases [7]. Unusual infectious agents particularly affect people with chronic diseases, especially immunocompromised patients [4][5][6][8][9][10][11]. Neutropenia is usually associated with mucosal or skin barrier disruption, and the indigenous colonizing pathogens are responsible for most infections.…”

Erysipelas in breast cancer patients after the radical mastectomy

“…Regarding the treatment of patients with erisipelas, diverse results were reported in literature [3,4,9,10]. Treatment with erythromycin is not usual but efficient.…”